Retatrutide
LY3437943 · Triple G · GIP/GLP-1/glucagon tri-agonist
Think of it as a multi-tool for weight and fat management.
Retatrutide is like a Swiss Army knife for your body's chemical signals. It's designed to tackle weight management and liver fat reduction by mimicking three natural hormones. This triple-action approach helps curb your appetite, boost energy use, and mobilize liver fat, all at the same time.
In trials, Retatrutide has shown impressive results, with participants losing significant weight and reducing liver fat content dramatically. It also helps in managing blood sugar levels, making it a potential powerhouse for those dealing with these challenges.
However, it's still in the testing phase and not yet available for general use. It promises a lot, but remember, it's not something you can grab off the shelf just yet.
Who it's for
- People struggling with weight management despite diet and exercise
- Individuals dealing with fatty liver issues looking for new solutions
- Those curious about cutting-edge weight loss science
Probably not for you if…
- Anyone looking for over-the-counter solutions
- Individuals who prefer well-established, FDA-approved treatments
- People uncomfortable with trying experimental therapies
Editorial summary for research context · Not medical advice
Mechanism of Action
Retatrutide is an investigational synthetic tri-agonist targeting the GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor activity is hypothesized to increase energy expenditure and hepatic fat mobilization beyond what GLP-1/GIP co-agonism delivers, while preserved GLP-1 activity offsets glucagon's glycemic effects. Developed by Eli Lilly and in Phase 3 trials — not FDA-approved. Only a prescribed, pharmaceutical-grade product under clinical supervision is appropriate for human use.
Researched Benefits
Weight reduction
Phase 2 trial reported mean weight loss of ~24% at the 12mg weekly dose over 48 weeks, the largest seen for any incretin-class agent to date.
- [Jastreboff et al. 2023]
Hepatic fat reduction
Phase 2 MASLD/NAFLD cohort showed liver fat content reductions exceeding 80% at higher doses over 48 weeks.
- [Sanyal et al. 2024]
Glycemic control
Phase 2 T2D trial reported HbA1c reductions of ~2.0 percentage points at the 12mg dose.
- [Rosenstock et al. 2023]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Clinical titration (investigational — prescription required)
- Dosage
- 2 mg
- Frequency
- once weekly
- Timing
- same day each week
- Cycle
- 4 weeks
Phase 2/3 trials titrate upward every 4 weeks to maintenance doses of 4/8/12mg. Investigational only — no approved formulation exists.
Reported Side Effects
- Gastrointestinal: nausea, vomiting, diarrhea, constipation (dose-dependent)
- Injection-site reactions
- Transient heart rate elevation observed at higher doses
- Hypoglycemia risk when combined with insulin or sulfonylureas
- Rare: pancreatitis signals reported
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy and lactation
- History of pancreatitis
Stacking Partners
Peptides commonly paired with Retatrutide in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Retatrutide. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredLMNT Electrolyte Drink Mix Variety Pack (30 sticks)
LMNT
GLP-1 agonism suppresses thirst — dehydration + electrolyte drop is the #1 source of the 'GLP-1 flu' complaint. LMNT targets that gap directly.
Psyllium Husk Fiber Capsules (500 ct)
NOW Foods
Constipation is the most-reported GLP-1 side effect. Daily soluble fiber addresses it without blunting the appetite effect.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Appetite suppression tanks protein intake if you don't actively defend it — protein powder is the cheapest floor against lean-mass loss.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
16:13I’m a Pathologist. Retatrutide is NOT Ozempic. It’s Biological Overdrive.
Dr. Amin Hedayat, MD
520.2K views · 16:13 · 1 month ago
11:01Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
This Is Not Covered - Dr. Ashley Froese
394.7K views · 11:01 · 2 months ago
13:15I Quit Retatrutide: My Final Verdict After 6 Months
Adrian Crook
206.6K views · 13:15 · 6 months ago
15:17Everything you need to know about Retatrutide, the newest GLP1 agonist
Dr. Kevin Joseph
205.6K views · 15:17 · 1 year ago
8:25Perfect Retatrutide Injection Every Single Time
David DeMesquita
160.9K views · 8:25 · 4 months ago
Research Papers
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. · New England Journal of Medicine · 2023
PubMed 37366315 →Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Rosenstock J, et al. · The Lancet · 2023
PubMed 37366672 →